BBIO
NASDAQ
$80.76
BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $104.78 (+29.74%)
Market Cap
$16B
Revenue 5Y CAGR
+131.56%
Free Cash Flow Yield
-2.75%
Beta (5Y)
1.02
Price Chart
Valuation
Market Cap$16B
P/S27.92
P/B123.68
Profitability
Total Revenue (TTM)$580M
Gross Profit (TTM)$552M
EBITDA-$520M
Profit Margin-85.6%
Operating Margin-54.5%
EPS-$3.77
Financial Health
Debt-to-Equity-116.4%
Free Cash Flow Yield-2.75%
Growth & Risk
EPS 5Y CAGR-3.14%
Revenue 5Y CAGR+131.56%
FCF 5Y CAGR-1.15%
Beta (5Y)1.02
Sharpe Ratio1.29